Rare Stock Picks In November 2023 - From 31 Discerning Analysts
https://seekingalpha.com/article/4656579-rare-stock-picks-in-november-2023-from-31-discerning-analysts?source=feed_tag_editors_picks
Dec 07, 2023 - Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.
0
Zevra seeks FDA nod for rare disease therapy arimoclomol
https://seekingalpha.com/news/4050701-zevra-stock-gains-nda-filing-arimoclomol?source=feed_sector_healthcare
Dec 27, 2023 - Zevra Therapeutics (ZVRA) has resubmitted a marketing application for its rare disease therapy arimoclomol to treat Niemann-Pick disease type C. Read more here.
0
Rare Stock Picks In December 2023 - From 34 Discerning Analysts
https://seekingalpha.com/article/4661020-draft-rare-stock-picks-december-2023-discerning-analysts?source=feed_tag_editors_picks
Jan 04, 2024 - Discover rare investment picks for December 2023 that you might have overlooked from analysts who make less-frequent recommendations. Read more here.
0
Tyra gets FDA Rare Pediatric Disease status for dwarfism drug
https://seekingalpha.com/news/4061754-tyra-gets-fda-rare-pediatric-disease-status-for-dwarfism-drug?source=feed_sector_healthcare
Feb 01, 2024 - Tyra Biosciences (TYRA) said the FDA has granted Rare Pediatric Disease Designation to its drug candidate TYRA-300 in the treatment of dwarfism. Read more here.
0
Ramstad: A rare moment of political practicality — and agreement — at Minnesota Chamber
https://www.startribune.com/ramstad-a-rare-moment-of-political-practicality-and-agreement-at-minnesota-chamber/600344253/
Feb 17, 2024 - The national immigration debate is a mess, but Minnesota's legislative leaders understand its complexity and economic importance.
0
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
https://seekingalpha.com/article/4675691-rare-stock-picks-in-february-2024-from-32-discerning-analysts?source=feed
Mar 05, 2024 - In our monthly Rare Stock Picks series, we're highlighting February 2024 investment picks. Click here for the list of February 2024 Buy recommendations.
0
StoneCo: A Very Rare Find At This Price
https://seekingalpha.com/article/4677227-stoneco-stne-stock-a-very-rare-find-at-this-price?source=feed
Mar 10, 2024 - StoneCo has shown strong revenue growth and improving financial results. Check out why we rate STNE stock as a strong buy.
0
Citi starts Catalyst at buy, cites rare disease drug portfolio
https://seekingalpha.com/news/4079636-citi-starts-catalyst-at-buy-cites-rare-disease-drug-portfolio?source=feed_sector_healthcare
Mar 14, 2024 - Citi started coverage of Catalyst Pharmaceuticals (CPRX) with a buy rating, citing the company’s rare disease drug portfolio that it views as largely de-risked. Read more here.
0
Lisata gets FDA rare pediatric disease status for lead drug
https://seekingalpha.com/news/4082189-lisata-gets-fda-rare-pediatric-disease-status-for-lead-drug?source=feed_sector_healthcare
Mar 21, 2024 - Lisata Therapeutics (LSTA) said its lead drug candidate LSTA1 has received Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma. Read more here.
0
Merck wins FDA approval of sotatercept for rare lung disease
https://seekingalpha.com/news/4084059-merck-wins-fda-approval-sotatercept-rare-lung-disease?source=feed_sector_healthcare
Mar 26, 2024 - Merck sotatercept, approved by the FDA for pulmonary arterial hypertension, offers hope for patients with pulmomary arterial hypertension. Read more here.
0
Page 1>